Cargando…

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis

OBJECTIVE: Research efforts have investigated therapies targeting tyrosine kinase signaling pathways. We performed a pooled analysis to determine the frequency of severe adverse effects in patients with soft tissue sarcoma treated with pazopanib, sorafenib and sunitinib. MATERIALS AND METHODS: We pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Que, Yi, Liang, Yao, Zhao, Jingjing, Ding, Ya, Peng, Ruiqing, Guan, Yuanxiang, Zhang, Xing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055834/ https://www.ncbi.nlm.nih.gov/pubmed/30050324 http://dx.doi.org/10.2147/CMAR.S164535

Ejemplares similares

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
por: Xiao, Wei, et al.
Publicado: (2018)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
por: Amdahl, Jordan, et al.
Publicado: (2014)

Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases
por: Read, William L., et al.
Publicado: (2016)

Comparison of the MAID (AI) and CAV/IE regimens with the predictive value of cyclic AMP-responsive element-binding protein 3 like protein 1 (CREB3L1) in palliative chemotherapy for advanced soft-tissue sarcoma patients
por: Xiao, Wei, et al.
Publicado: (2019)

Real-World Outcome and Prognostic Factors of Pazopanib in Advanced Soft Tissue Sarcoma
por: Alshamsan, Bader, et al.
Publicado: (2021)

Combined Use of the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios as a Prognostic Predictor in Patients with Operable Soft Tissue Sarcoma
por: Liang, Yao, et al.
Publicado: (2018)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Prognostic value of the fibrinogen/albumin ratio (FAR) in patients with operable soft tissue sarcoma
por: Liang, Yao, et al.
Publicado: (2018)

Effect of Acid‐Suppressive Strategies on Pazopanib Efficacy in Patients With Soft‐Tissue Sarcoma
por: Pisano, Sorana G., et al.
Publicado: (2019)

LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
por: Que, Yi, et al.
Publicado: (2019)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California
por: Seto, Tiffany, et al.
Publicado: (2019)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
por: Kim, Sang Kyum, et al.
Publicado: (2021)

Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response
por: Hong, Jung Yong, et al.
Publicado: (2023)

Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years
por: Shido, Yoji, et al.
Publicado: (2017)

Pneumothorax as adverse event in patients with lung metastases of soft tissue sarcoma treated with pazopanib: a single reference centre case series
por: Verschoor, Arie J, et al.
Publicado: (2014)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma
por: Aoyama, Takeshi, et al.
Publicado: (2023)

Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
por: Sheng, Xinan, et al.
Publicado: (2020)

Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Sorafenib and sunitinib: A dermatologist's perspective
por: Pragasam, Vijendran, et al.
Publicado: (2014)

Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
por: Nakano, Kenji, et al.
Publicado: (2016)

Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)
por: Ray-Coquard, Isabelle, et al.
Publicado: (2017)

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization
por: Verheijen, R. B., et al.
Publicado: (2017)

Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature
por: Nakahara, Yoshiro, et al.
Publicado: (2017)

Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8uqrd9ckiftqd9n6t77k0atbs4